Survival of the fittest or best adapted: HLA-dependent tumor development


https://doi.org/10.4081/jnai.2010.1654
Vol. 1 No. 1 (2010)
Submitted: 15 March 2010
Accepted: 23 April 2010
Published: 27 May 2010
Cancer, HLA, Ancestral Haplotypes, DNA, mRNA
Abstract Views: 1734
PDF: 624
HTML: 3507
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Giuseppe V. Masucci
    giuseppe.masucci@ki.se
    Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Emilia Andersson Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Lisa Villabona Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Hildur Helgadottir Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Kjell Bergfeldt Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Switzerland.
  • Federica Cavallo Molecular Biotechnology Center, Via Nizza 52, 10126 Torino, Italy, Italy.
  • Guido Forni Molecular Biotechnology Center, Via Nizza 52, 10126 Torino, Italy, Italy.
  • Soldano Ferrone University of Pittsburgh Cancer Institute, Departments of Surgery, Immunology and Pathology, School of Medicine, Pittsburgh, PA, USA, United States Minor Outlying Islands.
  • Aniruddha Choudhury Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Barbara Seliger Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany, Germany.
  • Rolf Kiessling Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
The major histocompatibility complex (MHC) comprises a set of genes that are critical to immunity and surveillance against neoplastic transformation. There is increasing evidence that the MHC antigens not only regulate antitumor immune responses in experimental animal models but directly correlate with survival and prognosis of patients with diverse types of cancers. MHC antigens may in the future function as potential biomarkers for prognosis and allow selection of cancer patients for intensive therapy.

Supporting Agencies

Cancer Society in Stockholm and Gustav 5th Jublilee fond, the motility grant #040226# from "NordForsk, Holbergs gate 1, NO-0166 Oslo, NORWAY" to the NCV

Masucci, G. V., Andersson, E., Villabona, L., Helgadottir, H., Bergfeldt, K., Cavallo, F., Forni, G., Ferrone, S., Choudhury, A., Seliger, B., & Kiessling, R. (2010). Survival of the fittest or best adapted: HLA-dependent tumor development. Journal of Nucleic Acids Investigation, 1(1), e9. https://doi.org/10.4081/jnai.2010.1654

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC